Clinical trials: Bone Cancer, open to volunteers
Cancer Patients Treated by Nephrotoxic Chemotherapy
Diagnostic Value of Tc-99mMDP Bone Scan in Assessment of Renal Functions in Cancer Patients Compared to Estimated Glomerular Filtration Rate.
-To compare the glomerular filtration rate obtained by Tc-99mMDP through Gate's method to estimated glomerular filtration rate (eGFR) and assess if we can do metastatic work up and evaluate renal function at a single Tc-99mMDP…
- Trial name
- NCT07123688
- Testing
- Tc-99mMDP bone scan
- Volunteers
- 40 people
- Sponsor
- Assiut University
Myeloid Disorders, Myelodysplastic Syndromes
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic…
- Conditions
- Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
- Trial name
- PREeMPT (NCT07572929)
- Testing
- Maintenance Therapy, No intervention
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Medical College of Wisconsin
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Polycythemia Vera
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any…
- Trial name
- MITHRIDATE (NCT04116502)
- Testing
- Ruxolitinib, Hydroxycarbamide, Interferon-Alpha
- Where
- 55 sites in United Kingdom
- Volunteers
- 586 people
- Sponsor
- University of Birmingham
Chronic Myeloid Leukemia
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
- Trial name
- NCT06817720
- Testing
- olverembatinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelomonocytic Leukemia
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Chronic Myelomonocytic Leukemia (CMML) is the most frequent of myelodysplastic/myeloproliferative syndromes, as defined by the WHO classification of myeloid malignancies.
- Trial name
- NCT03280888
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Methods of T Cell Depletion Trial (MoTD)
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- MoTD (NCT04888741)
- Testing
- Thymoglobulin, Cyclophosphamide, Cyclosporine
- Where
- 17 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Birmingham
Myeloproliferative Neoplasms
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
- Trial name
- NCT07008118
- Testing
- INCA035784
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Incyte Corporation
Myelofibrosis (MF), Polycythemia Vera
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation…
- Conditions
- Myelofibrosis (MF), Polycythemia Vera, Essential Thrombocythaemia
- Trial name
- NCT07863466
- Where
- Italy
- Volunteers
- 1,190 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Myelodysplastic Syndromes
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Background: Myelodysplastic syndromes (MDS) are disorders of blood stem cells that can develop into blood cancers. Treatment options are limited. To find better treatments, researchers need to better understand how MDS develops.
- Trial name
- NCT05588154
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Polycythemia Vera
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative…
- Trial name
- STANDARDIZE-PV (NCT07734272)
- Testing
- Standardized progress note
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Bone Cancer Metastatic, Radiofrequency Ablation
Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation
This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice.
- Conditions
- Bone Cancer Metastatic, Radiofrequency Ablation, Spine Metastases, Vertebral Metastasis
- Trial name
- ABLASPINE (NCT06716294)
- Testing
- Radiofrequency Ablation and Bone Augmentation
- Where
- Greece
- Volunteers
- 16 people
- Sponsor
- National and Kapodistrian University of Athens
Polycythemia Vera (PV), JAK2 Mutation
A Study of Ropeg-Interferon in People With Polycythemia Vera
The researchers are doing this study to find out whether it is practical (feasible) to stop treatment with ropeg-interferon (ropeg-INF) for some people with polycythemia vera (PV) with a change (mutation) in theJa nus kinase 2…
- Trial name
- NCT07886801
- Testing
- Ropeginterferon
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bone Tumor, Bone Cancer
Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled Trial
The goal of this clinical trial is to learn if adding a medical payment case management service to the hospital's usual follow-up care can reduce the financial hardship of cancer treatment in patients of any age, including…
- Trial name
- NCT07888244
- Testing
- Medical payment case management service
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai 6th People's Hospital
Chronic Myeloid Leukemia (CML)
Study of CD38 and CD56 in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
- Trial name
- NCT07740603
- Testing
- cd 38 and cd 56
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Diamond Blackfan Anemia, Dyskeratosis Congenita
Cancer in Inherited Bone Marrow Failure Syndromes
Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.
- Conditions
- Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome
- Trial name
- NCT00027274
- Where
- 2 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Donor lymphocyte infusion (DLI) based on minimal residual disease (MRD) has been widely adopted worldwide to enhance the graft-versus-leukemia effect following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT07319793
- Testing
- Prophylactic DLI, Preemptive DLI
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Leukemia, Myelomonocytic Leukemia, Chronic
Cohort of Patients With Chronic Myelomonocytic Leukemia
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or…
- Trial name
- MYELOMONO-3 (NCT07512882)
- Testing
- Sampling
- Where
- 24 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
This study is a clinical trial to evaluate the tolerability and pharmacokinetics of TQB3455 tablets in patients with hematological malignancies. TQB3455 is an isocitrate dehydrogenase 2(IDH2) inhibitor .
- Trial name
- NCT06550713
- Testing
- TQB3455 tablet+Azacitidine for Injection
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.